Docoh
Loading...

PHAS PhaseBio Pharmaceuticals

Employees

Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM


On June 3, 2021, PhaseBio Pharmaceuticals, Inc. (the “Company”) held its 2021 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered three proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2021 (the “Proxy Statement”). Of the 47,952,033 shares outstanding as of the record date, 39,245,872 shares, or 81.84%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

Proposal No. 1: Election of Directors

The Company’s stockholders elected the three Class III nominees named in the Proxy Statement to serve as directors until the 2024 annual meeting of stockholders and until their respective successors are elected and qualified, or, if sooner, until the director’s death, resignation or removal, by the following votes:

NameForWithheldBroker Non-Votes
Nancy J. Hutson30,823,2452,206,5356,216,092
Caroline M. Loewy31,775,0331,254,7476,216,092
Alex C. Sapir32,161,405868,3756,216,092


Proposal No. 2: Approval of the 2018 Equity Incentive Plan, as amended

The Company’s stockholders approved the Company’s 2018 Equity Incentive Plan, as amended, to increase the automatic increase to the share reserve that occurs on January 1st of each calendar year until (and including) January 1, 2028 from 3% to 4% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year, by the following votes:

ForAgainstAbstainBroker Non-Votes
29,008,0473,995,61826,1156,216,092


Proposal No. 3: Ratification of the selection of KPMG LLP

The Company’s stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021, by the following votes:

ForAgainstAbstainBroker Non-Votes
39,166,26566,91912,687